French Lisa 4

What Happened

• Lisa French, EVP & Chief Commercial Officer of Keenova Therapeutics plc, received a grant of 51,794 restricted stock units (RSUs) on 2026-02-25. The RSUs are recorded as a derivative award at $0.00 per share (no cash paid at grant); they will settle one ordinary share per RSU upon vesting.

Key Details

• Transaction date: 2026-02-25; Form 4 filed: 2026-02-26 (period of report: 2026-02-25).
• Award: 51,794 RSUs; acquisition price reported $0.00 (derivative award).
• Vesting: RSUs will vest ratably on each of the first three anniversaries beginning Feb 25, 2027 (per filing footnote).
• Settlement: Each RSU converts to one ordinary share upon vesting (per filing footnote).
• Shares owned after transaction: Not reported on this Form 4.
• No indication of a 10b5-1 plan, tax withholding, or late filing noted in the filing remarks.

Context

• This is a standard equity compensation grant (award of RSUs) commonly used to align executive incentives with shareholder value; it is not an open-market purchase or sale. The award has no immediate cash value until vested and settled, and its eventual worth will depend on Keenova’s share price at vesting.